Research Analysts Set Expectations for BCYC Q1 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for Bicycle Therapeutics in a research note issued to investors on Monday, December 16th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.93) per share for the quarter, up from their prior forecast of ($0.99). HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Bicycle Therapeutics’ Q2 2025 earnings at ($0.96) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($4.14) EPS, FY2027 earnings at ($3.49) EPS and FY2028 earnings at ($2.12) EPS.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. During the same period in the previous year, the business earned ($1.26) EPS. The firm’s revenue was down 50.0% on a year-over-year basis.

BCYC has been the subject of several other research reports. JMP Securities cut their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $35.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Finally, Stephens started coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Bicycle Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $35.25.

Bicycle Therapeutics Stock Up 1.1 %

Shares of BCYC opened at $15.31 on Thursday. Bicycle Therapeutics has a 12 month low of $12.17 and a 12 month high of $28.67. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -4.65 and a beta of 0.86. The company has a 50-day moving average price of $22.45 and a two-hundred day moving average price of $22.66.

Insider Activity at Bicycle Therapeutics

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.16. Following the transaction, the chief accounting officer now directly owns 19,241 shares in the company, valued at approximately $483,141.51. This trade represents a 24.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 500,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were purchased at an average price of $15.34 per share, with a total value of $7,670,000.00. Following the transaction, the director now owns 9,995,274 shares of the company’s stock, valued at $153,327,503.16. The trade was a 5.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 10,840 shares of company stock valued at $259,128 over the last ninety days. 8.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Bicycle Therapeutics by 0.6% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock worth $17,975,000 after purchasing an additional 4,976 shares during the last quarter. Pinnacle Associates Ltd. raised its stake in shares of Bicycle Therapeutics by 202.2% during the second quarter. Pinnacle Associates Ltd. now owns 242,001 shares of the company’s stock worth $4,898,000 after buying an additional 161,911 shares during the last quarter. Natixis Advisors LLC acquired a new position in Bicycle Therapeutics in the second quarter valued at approximately $261,000. TD Asset Management Inc boosted its stake in Bicycle Therapeutics by 76.7% in the second quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after acquiring an additional 42,200 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Bicycle Therapeutics by 97.2% during the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock worth $6,614,000 after acquiring an additional 161,100 shares during the period. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.